161 related articles for article (PubMed ID: 35016731)
1. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
Müller L; Hahn F; Jungmann F; Mähringer-Kunz A; Stoehr F; Halfmann MC; Pinto Dos Santos D; Hinrichs J; Auer TA; Düber C; Kloeckner R
Cancer Imaging; 2022 Jan; 22(1):5. PubMed ID: 35016731
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE.
Fronda M; Doriguzzi Breatta A; Gatti M; Calandri M; Maglia C; Bergamasco L; Righi D; Faletti R; Fonio P
Eur Radiol; 2021 Sep; 31(9):6578-6588. PubMed ID: 33738601
[TBL] [Abstract][Full Text] [Related]
3. Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study.
Müller L; Mähringer-Kunz A; Auer TA; Fehrenbach U; Gebauer B; Haubold J; Theysohn JM; Kim MS; Kleesiek J; Diallo TD; Eisenblätter M; Bettinger D; Steinle V; Mayer P; Zopfs D; Pinto Dos Santos D; Kloeckner R
Eur Radiol; 2023 Feb; 33(2):1031-1039. PubMed ID: 35986768
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
[TBL] [Abstract][Full Text] [Related]
5. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
6. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
7. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Müller L; Hahn F; Mähringer-Kunz A; Stoehr F; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Pitton MB; Düber C; Fehrenbach U; Auer TA; Gebauer B; Kloeckner R
United European Gastroenterol J; 2022 Feb; 10(1):41-53. PubMed ID: 34918471
[TBL] [Abstract][Full Text] [Related]
8. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models.
Vosshenrich J; Zech CJ; Heye T; Boldanova T; Fucile G; Wieland S; Heim MH; Boll DT
Eur Radiol; 2021 Jun; 31(6):4367-4376. PubMed ID: 33274405
[TBL] [Abstract][Full Text] [Related]
9. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
11. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC.
Müller L; Kloeckner R; Mähringer-Kunz A; Stoehr F; Düber C; Arnhold G; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Hahn F
Eur Radiol; 2022 Sep; 32(9):6302-6313. PubMed ID: 35394184
[TBL] [Abstract][Full Text] [Related]
12. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
13. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
[TBL] [Abstract][Full Text] [Related]
14. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
16. [Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)].
Herber SC; Otto G; Woerns M; Moench C; Kanzler S; Junginger T; Schneider J; Schuchmann M; Kummer I; Manzl N; Düber C; Pitton MB
Rofo; 2007 Mar; 179(3):289-99. PubMed ID: 17325996
[TBL] [Abstract][Full Text] [Related]
17. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
[TBL] [Abstract][Full Text] [Related]
18. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome.
Yu SCH; Hui JW; Li L; Cho CC; Hui EP; Chan SL; Yeo WM
Cardiovasc Intervent Radiol; 2022 Feb; 45(2):172-181. PubMed ID: 34604920
[TBL] [Abstract][Full Text] [Related]
20. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
[No Abstract] [Full Text] [Related]
[Next] [New Search]
